Aller au contenu

514 606-3350

info@cliniqueomicron.ca​

FR / EN
Logo - Clinique Omicron
Make an appointment
Microbiology & Infectious Serology

CMV IgG (Cytomegalovirus : IgG antibodies)

Conduct this analysis

Blood draws at our service locations in Quebec. A healthcare professional can also review your results with you.

Le dosage des anticorps IgG dirigés contre le cytomégalovirus (CMV IgG) est une analyse sérologique qui permet de déterminer si une personne a été exposée au cytomégalovirus à un moment quelconque de sa vie, une infection passée laissant une immunité humorale persistante matérialisée par la présence durable d'anticorps IgG spécifiques anti-CMV dans le sérum. Le cytomégalovirus est un herpèsvirus ubiquitaire (herpèsvirus humain de type 5, HHV-5) caractérisé par sa capacité à établir une latence à vie dans l'organisme après la primo-infection, principalement dans les monocytes et les cellules myéloïdes, et à se réactiver en cas d'immunodépression. Sa séroprévalence est considérable : environ 50 à 70 % des adultes canadiens sont séropositifs pour le CMV IgG, avec des variations importantes selon l'origine géographique, le statut socio-économique et l'âge (séroprévalence supérieure à 80–90 % dans les pays en développement et les communautés défavorisées). Dans la grande majorité des personnes immunocompétentes, la primo-infection à CMV est asymptomatique ou se manifeste par un tableau de mononucléose-like bénin et auto-résolutif. L'enjeu clinique majeur du CMV réside dans trois populations spécifiques pour lesquelles l'infection, primo-infection, réinfection ou réactivation, peut avoir des conséquences sévères ou fatales : les femmes enceintes (risque de transmission fœtale avec séquelles neurodéveloppementales), les personnes immunodéprimées (transplantés d'organes solides ou de cellules souches hématopoïétiques, patients VIH avec CD4 bas, patients sous immunosuppresseurs) et les nouveau-nés (CMV congénital, première cause infectieuse de surdité neurosensorielle et de retard mental non génétique dans les pays développés). La sérologie CMV IgG seule ne permet pas de dater l'infection ni d'affirmer une infection active, elle doit être interprétée en parallèle avec les IgM anti-CMV, l'index d'avidité des IgG et la PCR CMV quantitative selon le contexte clinique.

What this test measures

  • CMV IgG: Immunoglobulin G antibodies specifically directed against cytomegalovirus proteins. They appear 2 to 4 weeks after primary infection, peak at 6 to 12 weeks, and then persist at stable, detectable levels for life. Their presence indicates past exposure to CMV (recent or old infection) and acquired humoral immunity. They alone do not distinguish between an old infection and a recent primary infection without measurement of avidity.
  • CMV IgM (often measured as a complement): immunoglobulin M antibodies appearing early during primary infection (as early as 1-2 weeks) and during reactivations; they usually persist for 3 to 6 months but can last up to 12 months or longer in some cases, their isolated presence therefore does not necessarily indicate a recent primary infection
  • CMV IgG Avidity Index: a measure of the binding strength (avidity) of anti-CMV IgG antibodies to their antigens, low avidity (< 30–40 %, depending on the laboratory) at the onset of infection, gradually increasing over 3 to 6 months to high avidity (> 60 %) in established infection; a key parameter for dating primary infection, particularly during pregnancy (high avidity in the first trimester = infection prior to pregnancy, therefore no risk of current primary infection)
  • Quantitative PCR for Cytomegalovirus (CMV viral load): Detection and quantification of CMV DNA in blood (plasma or leukocytes), urine, bronchoalveolar lavage fluid (BALF), cerebrospinal fluid (CSF), or stool, depending on the context. Essential for diagnosing active infection and monitoring treatment in immunocompromised individuals. Not part of the standard serological workup, but the reference test for at-risk situations.

Results Interpretation

Serological profile IgG IgM Interpretation and course of action
No CMV exposure (seronegative) Negative Negative Never infected with CMV, absence of acquired immunity; presents a risk of primary infection if exposed (contact with young children in daycare, unprotected sexual intercourse, transfusion or transplant from a CMV+ donor); important preventive measures in seronegative pregnant women; crucial importance for donor/recipient CMV matching in transplantation
Old infection (acquired immunity) Positive Negative Past infection with lasting immunity; CMV remains latent in the body for life; risk of reactivation in cases of immunosuppression; in seropositive pregnant women: risk of reinfection with a new strain or reactivation (risk of fetal transmission of 0.5–2 % vs. 30–40 % in primary infection); in transplant candidates: known CMV-positive status of the recipient, will guide post-transplant prophylaxis or preemptive strategy
Probable recent primary infection Positive Positive Combined IgG+ and IgM+ results, suggestive of a recent primary infection; supplement with measurement of the IgG avidity index: if low avidity (< 30–40 %) → primary infection within the last 3 months (high risk of fetal transmission during pregnancy); if high avidity (> 60 %) → past infection with persistent IgM (common and reassuring finding) or reactivation; quantitative CMV PCR if immunocompromised
Isolated IgM positive (IgG negative) Negative Positive Rare situation possibly corresponding to a very early primary infection before the appearance of IgG (serological window); false positive IgM due to cross-reaction (rheumatoid factor, EBV, other herpesviruses) - common; serological follow-up at 2-3 weeks to confirm the appearance of IgG; CMV PCR if suggestive symptoms
CMV reactivation in the immunocompromised Positive Variable Serology is not the reference test for diagnosing reactivation in immunocompromised patients, the antibody response may be absent or insufficient; diagnosis relies on quantitative CMV PCR in plasma; treatment thresholds are defined by transplant teams according to graft type and individual risk; weekly CMV PCR monitoring post-transplantation according to institutional protocols

Clinical indications for CMV IgG testing

  • Pre-nuptial or pre-conception check-up: determination of CMV serological status in women of childbearing age to identify seronegative women at risk of primary infection during pregnancy; information and preventive measures if seronegative (hand washing after contact with secretions of young children - main source of contamination for pregnant women, avoid sharing utensils and mouth-to-mouth kissing with young children).
  • Surveillance during pregnancy: CMV serology (IgG + IgM) is indicated if the pregnant woman presents with mononucleosis-like symptoms, if fetal anomalies suggestive of congenital CMV are detected on ultrasound (ventriculomegaly, bowel hyperechogenicity, intracranial calcifications, intrauterine growth restriction, microcephaly), or as part of a voluntary prenatal diagnostic approach. If seroconversion is confirmed: amniocentesis with CMV PCR on amniotic fluid after 21 weeks of amenorrhea to assess fetal transmission.
  • Pre-transplant assessment (solid organ and hematopoietic stem cells): systematic donor and recipient CMV serology : CMV D+/R− status (donor seropositive, recipient seronegative) is the situation with the highest risk of post-transplant CMV disease; it will guide prophylactic strategy (oral valganiclovir for 3–6 months post-transplantation) or preemptive strategy (weekly PCR surveillance with treatment if threshold is exceeded)
  • Immunodeficiency assessment (HIV, hematological disorders, chemotherapy): CMV status determination to evaluate reactivation risk; active CMV disease (retinitis, colitis, pneumopathy, encephalitis) occurs mainly when CD4 count is < 50 cells/mm³ in HIV; preventive treatment with valganciclovir in high-risk situations
  • Clinical presentation of CMV mononucleosis (heterophile-negative mononucleosis): prolonged fever, marked asthenia, mononucleosis syndrome (atypical lymphocytes on complete blood count) with a negative Monospot test - suspect CMV and EBV; CMV serology (IgG + IgM + avidity) and EBV; PCR if immunocompromised
  • Evaluation of prolonged unexplained fever: CMV can cause a persistent febrile syndrome even in the immunocompetent; this should be considered in the evaluation of prolonged fever without an identified source.

Congenital Cytomegalovirus (CMV) : Specific Challenges

  • Epidemiology: Congenital CMV is the most common congenital infection in developed countries, affecting 0.5 to 1% of all live-born infants; in Canada, approximately 3,000 to 4,000 newborns are infected each year; 10–15% of infected newborns are symptomatic at birth (hepatosplenomegaly, microcephaly, petechiae, jaundice, chorioretinitis); 85–90% are asymptomatic, but 10–15% of these will develop late sequelae (sensorineural hearing loss, cognitive impairments)
  • Risk of fetal transmission: 30–40% % in cases of maternal primary infection during the first trimester (highest risk of severe complications); 1–2 % in cases of reactivation or reinfection in the presence of pre-existing immunity; maternal primary infection during the first trimester is the situation posing the highest risk
  • Neonatal diagnostics: CMV PCR on urine or saliva within the first 3 weeks of life (gold standard), after this period, a positive PCR may reflect postnatal infection acquired through breast milk (benign) rather than congenital infection
  • Treatment: oral valganciclovir for 6 months in symptomatic newborns with central nervous system involvement, demonstrated reduction in auditory and neurodevelopmental sequelae at 2 years in the CASG 112 trial
  • Prevention: no vaccine currently available; strict hygiene measures for pregnant women who are seronegative: careful hand washing after diaper changes or contact with young children's nasal secretions, avoid sharing glasses, cutlery, toothbrushes with children under 3 years old, and avoid mouth-to-mouth kisses on their lips
ℹ️ In pregnant women, the simultaneous presence of anti-CMV IgG and IgM does not automatically equate to a recent primary infection, IgM can persist for several months after an old infection, and false positives are frequent. The IgG avidity index is the decisive test: high avidity in the first trimester of pregnancy reliably rules out a primary infection within the last 3 months and avoids unwarranted anxiety and unnecessary invasive investigations.

Reference values and units

  • CMV IgG: expressed in arbitrary units per milliliter (AU/mL) or as an index depending on the reagent used; positivity thresholds vary by analytical platform, usually negative if 1.0 AU/mL; refer to the reference values of the laboratory performing the analysis
  • CMV IgM: positive / negative / indeterminate according to signal/cut-off ratio; IgM are subject to false positives (rheumatoid factor, cross-reactions with other herpesviruses), always interpret in clinical context
  • CMV IgG Avidity Index: low avidity < 30–40 % (depending on the laboratory) = probable recent infection (< 3 months); high avidity > 60 % = past infection; gray zone 30–60 %, interpretation based on context
  • PCR CMV (viral load): expressed in copies/mL or IU/mL (international units per milliliter); treatment thresholds in transplant recipients are defined by each transplant center according to the type of graft and individual risk; detectable PCR in the context of symptoms in an immunocompromised patient requires treatment without waiting for an arbitrary threshold
Situations requiring immediate medical attention

All transplanted or immunosuppressed patients (HIV with low CD4 count, intensive chemotherapy) presenting with fever, decreased visual acuity (flashes, floaters – suspect CMV retinitis), abdominal pain with bloody diarrhea (CMV colitis), or febrile dyspnea (CMV pneumonia) must be urgently evaluated with quantitative CMV PCR and infectious disease consultation. Pregnant women with prolonged fever or confirmed CMV seroconversion should be promptly referred for maternal-fetal medicine consultation to discuss fetal assessment (reference ultrasound, amniocentesis if indicated).

For the prescription of CMV serology as part of a prenuptial, preconception, prenatal, or pre-transplant assessment, Clinique Omicron offers consultations at our Quebec branches as well as via telemedicine. To book an appointment, visit cliniqueomicron.ca.

Consult at Clinique Omicron

À Clinique Omicron, une consultation médicale permet de demander et d'interpréter la sérologie du CMV (cytomégalovirus : IgG, IgM, avidité) selon votre situation, par exemple avant une grossesse, pendant une grossesse ou dans un bilan d'immunodépression. Selon les résultats, une orientation vers un infectiologue, un hématologue ou un néphrologue peut être faite. Consultations en clinique ou en téléconsultation. Au moment de réserver, indiquez le motif de votre consultation. Pour faire une demande de rendez-vous, Choose your online service.

The content of this page is provided for informational purposes only and does not substitute for the advice of a qualified healthcare professional. CMV serology interpretation should always be performed in a clinical context by a physician, particularly in pregnant women and immunocompromised patients.

Omicron Clinic

Need to consult a doctor?

In-person or via telemedicine, anywhere in Quebec.

We accept insurance. Telemedicine consultations available 7 days a week. No family doctor required.